Evidence map›Paper›PMID 40551789›Full record

ArticleERJ open research2025

Circulating prostasin is an independent marker of mortality risk in patients with idiopathic pulmonary fibrosis.

Jamie L Todd, Courtney Page, Peitao Wu, John A Belperio, Toby M Maher, Scott M Palmer, Thomas B Leonard, Christian Hesslinger, Megan L Neely, Thomas Schlange

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jamie L ToddDuke Clinical Research Institute, Durham, NC, USA.
Courtney PageDuke Clinical Research Institute, Durham, NC, USA.
Peitao WuBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
John A BelperioDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Toby M MaherKeck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0001-7192-9149
Scott M PalmerDuke Clinical Research Institute, Durham, NC, USA.
Thomas B LeonardBoehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Christian HesslingerBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Megan L NeelyDuke Clinical Research Institute, Durham, NC, USA.
Thomas SchlangeBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostasin is expressed in the lung epithelium where it regulates fluid and electrolyte balance Methods: Patients with IPF came from the IPF-PRO Registry. Controls without lung disease had a similar age/sex distribution. Prostasin was quantified in plasma taken at enrolment and, in the IPF cohort, ∼6 months post-enrolment, by immunoassay. Linear regression was used to compare prostasin levels at enrolment in patients with IPF Results: Prostasin level at enrolment was higher in patients with IPF (n=624) Conclusions: Circulating prostasin is an independent marker of mortality risk in patients with IPF.

Identifiers

PMID40551789
PMCPMC12183712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.